AI Automation And Healthcare Data Scale Will Shape A Fairly Valued Future

Catalysts

About Waystar Holding

Waystar Holding provides AI-enabled revenue cycle management and payment software that helps health care providers get paid accurately and efficiently.

What are the underlying business or industry changes driving this perspective?

• Although the company now pairs financial and clinical data at scale through the Iodine acquisition and coverage of roughly 1 in 3 U.S. hospital discharges, the push toward more automated reimbursement workflows could pressure pricing as providers expect a greater share of efficiency gains. This may cap long term revenue per client and limit net margin expansion.
• Although management highlights a record implementation backlog and larger million dollar bookings tied to AI agents, the 6 to 18 month ramp time for these contracts means any delays or slower adoption of autonomous revenue cycle tools could leave reported revenue tracking close to current low double digit guidance rather than meaningfully lifting earnings.
• Although AltitudeAI and other agents currently touch roughly 40% of revenue and are contributing to 30% of new bookings, growing use of general purpose LLMs by health systems and technology partners could compress the premium Waystar can charge for AI. This may temper subscription revenue growth and keep EBITDA margins near the stated 40% to 42% range.
• Although the company processes more than 7 billion annual transactions and connects over 1 million providers to payers, continued industry moves toward direct connectivity and alternative payment rails could over time reduce transaction volumes flowing through the network. This may put a ceiling on volume based revenue and associated cash generation.
• Although management expects to realize over 90% of Iodine cost synergies in 2026 and is reinvesting in AI and go to market, ongoing spend to keep pace with rapid advances in agentic automation and cybersecurity could offset much of the synergy benefit. This may limit further EBITDA margin improvement and constrain free cash flow growth.

Assumptions

This narrative explores a more pessimistic perspective on Waystar Holding compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming Waystar Holding's revenue will grow by 12.4% annually over the next 3 years.
• The bearish analysts assume that profit margins will increase from 10.2% today to 14.8% in 3 years time.
• The bearish analysts expect earnings to reach $231.1 million (and earnings per share of $1.14) by about March 2029, up from $112.1 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $320.9 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 36.1x on those 2029 earnings, down from 45.5x today. This future PE is lower than the current PE for the US Healthcare Services industry at 39.2x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 9.09%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• If health care providers keep adopting AI-powered revenue cycle tools at the pace suggested by management, including AltitudeAI contributing to roughly 40% of revenue and about 30% of new bookings in 2025, that level of product traction could support higher revenue and earnings than implied by a flat share price view, especially if ROI led sales momentum persists.
• The company is pairing one of the larger U.S. health care payment data sets, with more than 7 billion annual transactions and clinical data covering roughly 1 in 3 U.S. hospital discharges, and if this data advantage keeps compounding model performance, it could support stronger client retention, pricing power and cross sell, which would be supportive for revenue and net margins.
• Waystar reported 2025 revenue of US$1.1b with adjusted EBITDA of US$462 million at a 42% margin, and guided 2026 revenue to US$1.274b to US$1.294b with adjusted EBITDA of US$530 million to US$540 million at about a 42% margin. If the company continues to convert a high share of EBITDA into unlevered free cash flow while keeping net leverage around 3x and delevering, the balance sheet and cash generation profile could support higher valuation multiples and earnings based expectations.
• Management describes a record implementation backlog, record Q4 bookings and a robust pipeline, including 15 to 20 million dollar plus bookings in each of the last two quarters of 2025. If those contracts ramp within the 6 to 18 month window as expected, the contribution to subscription and transaction volumes could lift revenue growth and support earnings beyond what would be consistent with a flat share price.
• The integration of Iodine Software, which contributed US$31 million of revenue in Q4 2025 with more than 1,000 hospitals and only 35% overlap, is expected to deliver over 90% of US$15 million cost synergies in 2026 and expand cross sell opportunities. If both the cost savings and broader addressable market continue to support the combined platform, that could sustain or increase EBITDA margins and earnings rather than support a stagnant valuation.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Waystar Holding is $27.35, which represents up to two standard deviations below the consensus price target of $37.0. This valuation is based on what can be assumed as the expectations of Waystar Holding's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $45.0, and the most bearish reporting a price target of just $27.0.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $1.6 billion, earnings will come to $231.1 million, and it would be trading on a PE ratio of 36.1x, assuming you use a discount rate of 9.1%.
  
• Given the current share price of $26.58, the analyst price target of $27.35 is 2.8% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.